PURPOSE: To determine the relative frequency with which Kaposi's sarcoma-associated herpesvirus/HHV-8 (KSHV) DNA is detected in peripheral-blood mononuclear cells (PBMCs) and in plasma of patients with AIDS-KS and AIDS-associated non-Hodgkin's lymphoma (NHL; AIDS-NHL); to determine whether the presence of viral DNA in plasma reflects lysis of tumor cells or reflects the presence of viremia (ie, virion-encapsidated DNA); and to determine the effect of lymphoma therapy on KSHV DNA. PATIENTS AND METHODS: Samples were obtained from patients enrolled in AIDS Malignancy Consortium clinical trials and from healthy donors. Real time PCR was used to quantify KSHV DNA in peripheral blood mononuclear cells (PBMC) and plasma. DNase digestion and fragment size determination studies were used to characterize the DNA detected. RESULTS: In patients with AIDS-KS, KSHV DNA was detected in PBMC (54%) and in plasma (62%). In patients with AIDS-NHL, KSHV DNA was detected in PBMC (19%) and in plasma (22%). Median copy numbers also differed. KSHV DNA in plasma appeared to be encapsidated. In six patients with AIDS-NHL who were treated with chemotherapy (with or without rituximab), KSHV copy number declined in PBMC and in plasma. CONCLUSION: KSHV DNA is sometimes detected in PBMC or in plasma of patients with AIDS-NHL without KS. Among patients with KSHV DNA detected in PBMC or in plasma, copy number does not distinguish between patients with AIDS-NHL and AIDS-KS. KSHV DNA in plasma likely reflects viremia and not simply lysis of tumor or other KSHV-infected cells. KSHV DNA copy number in PBMC and in plasma declined with lymphoma-directed cytotoxic chemotherapy in each of the six patients studied.
PURPOSE: To determine the relative frequency with which Kaposi's sarcoma-associated herpesvirus/HHV-8 (KSHV) DNA is detected in peripheral-blood mononuclear cells (PBMCs) and in plasma of patients with AIDS-KS and AIDS-associated non-Hodgkin's lymphoma (NHL; AIDS-NHL); to determine whether the presence of viral DNA in plasma reflects lysis of tumor cells or reflects the presence of viremia (ie, virion-encapsidated DNA); and to determine the effect of lymphoma therapy on KSHV DNA. PATIENTS AND METHODS: Samples were obtained from patients enrolled in AIDS Malignancy Consortium clinical trials and from healthy donors. Real time PCR was used to quantify KSHV DNA in peripheral blood mononuclear cells (PBMC) and plasma. DNase digestion and fragment size determination studies were used to characterize the DNA detected. RESULTS: In patients with AIDS-KS, KSHV DNA was detected in PBMC (54%) and in plasma (62%). In patients with AIDS-NHL, KSHV DNA was detected in PBMC (19%) and in plasma (22%). Median copy numbers also differed. KSHV DNA in plasma appeared to be encapsidated. In six patients with AIDS-NHL who were treated with chemotherapy (with or without rituximab), KSHV copy number declined in PBMC and in plasma. CONCLUSION: KSHV DNA is sometimes detected in PBMC or in plasma of patients with AIDS-NHL without KS. Among patients with KSHV DNA detected in PBMC or in plasma, copy number does not distinguish between patients with AIDS-NHL and AIDS-KS. KSHV DNA in plasma likely reflects viremia and not simply lysis of tumor or other KSHV-infected cells. KSHV DNA copy number in PBMC and in plasma declined with lymphoma-directed cytotoxic chemotherapy in each of the six patients studied.
Authors: Dimitra Bourboulia; Diana Aldam; Dimitrios Lagos; Elizabeth Allen; Ian Williams; David Cornforth; Andrew Copas; Chris Boshoff Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: J Yang; Q Tao; I W Flinn; P G Murray; L E Post; H Ma; S Piantadosi; M A Caligiuri; R F Ambinder Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: Thomas B Campbell; Katherine A Staskus; Joy Folkvord; Irene E White; James Neid; Xing-Quan Zhang; Elizabeth Connick Journal: J Infect Dis Date: 2004-12-23 Impact factor: 5.226
Authors: A Scott Laney; Michael J Cannon; Harold W Jaffe; Margaret K Offermann; Chin-Yih Ou; Kay W Radford; Mitesh M Patel; Thomas J Spira; Clifford J Gunthel; Philip E Pellett; Sheila C Dollard Journal: AIDS Date: 2007-07-31 Impact factor: 4.177
Authors: Mark Bower; Tom Powles; Sarah Williams; Tom Newsom Davis; Mark Atkins; Silvia Montoto; Chloe Orkin; Andy Webb; Martin Fisher; Mark Nelson; Brian Gazzard; Justin Stebbing; Peter Kelleher Journal: Ann Intern Med Date: 2007-12-18 Impact factor: 25.391
Authors: C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary Journal: Nat Med Date: 1995-12 Impact factor: 53.440
Authors: Rachel A Bender Ignacio; Jeannette Y Lee; Michelle A Rudek; Dirk P Dittmer; Richard F Ambinder; Susan E Krown Journal: J Acquir Immune Defic Syndr Date: 2016-05-01 Impact factor: 3.731
Authors: Daniel C Beachler; Lan L Gellert; Lisa P Jacobson; Richard F Ambinder; Elizabeth C Breen; Otoniel Martínez-Maza; Charles S Rabkin; Charles C Rabkin; Richard A Kaslow; Gypsyamber D'Souza Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Meir Shamay; Nicholas Hand; M Victor Lemas; Henry B Koon; Susan E Krown; John Wrangle; Prashant Desai; Juan Carlos Ramos; Richard F Ambinder Journal: J Infect Dis Date: 2012-02-22 Impact factor: 5.226
Authors: Kristen M Tamburro; Dongmei Yang; Jessica Poisson; Yuri Fedoriw; Debasmita Roy; Amy Lucas; Sang-Hoon Sin; Nadia Malouf; Vincent Moylan; Blossom Damania; Stephan Moll; Charles van der Horst; Dirk P Dittmer Journal: Virology Date: 2012-08-24 Impact factor: 3.616
Authors: Maryjo Lechowicz; Dirk P Dittmer; Jeannette Y Lee; Susan E Krown; William Wachsman; David Aboulafia; Bruce J Dezube; Lee Ratner; Jonathan Said; Richard F Ambinder Journal: Clin Infect Dis Date: 2009-12-15 Impact factor: 9.079
Authors: Erin G Reid; Adrienne Suazo; Shelly Y Lensing; Dirk P Dittmer; Richard F Ambinder; Frank Maldarelli; Robert J Gorelick; David Aboulafia; Ronald Mitsuyasu; Mark A Dickson; William Wachsman Journal: Clin Cancer Res Date: 2019-10-17 Impact factor: 12.531